Using gene expression profiling to identify a prognostic molecular spectrum in gliomas

被引:26
作者
Shirahata, Mitsuaki [1 ,2 ]
Oba, Shigeyuki [3 ]
Iwao-Koizumi, Kyoko [1 ]
Saito, Sakae [1 ]
Ueno, Noriko [1 ]
Oda, Masashi [2 ]
Hashimoto, Nobuo [2 ]
Ishii, Shin [3 ]
Takahashi, June A. [2 ]
Kato, Kikuya [1 ]
机构
[1] Osaka Med Ctr Canc & Cardiovasc Dis, Res Inst, Higashinari Ku, Osaka 5378511, Japan
[2] Kyoto Univ, Grad Sch Med, Dept Neurosurg, Shogoin Sakyoku, Kyoto 6068507, Japan
[3] Nara Inst Sci & Technol, Lab Theoret Life Sci, Nara 6300192, Japan
来源
CANCER SCIENCE | 2009年 / 100卷 / 01期
关键词
THERAPY-ONCOLOGY-GROUP; HIGH-GRADE GLIOMA; MALIGNANT GLIOMAS; GLIOBLASTOMA-MULTIFORME; RADIATION-THERAPY; CELL INVASION; BREAST-CANCER; GROWTH-FACTOR; PHASE-II; IN-VIVO;
D O I
10.1111/j.1349-7006.2008.01002.x
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Histopathological classification of gliomas is often clinically inadequate due to the diversity of tumors that fall within the same class. The goal of the present study was to identify prognostic molecular features in diffusely infiltrating gliomas using gene expression profiling. We selected 3456 genes expressed in gliomas, including 3012 genes found in a gliomal expressed sequence tag collection. The expression levels of these genes in 152 gliomas (100 glioblastomas, 21 anaplastic astrocytomas, 19 diffuse astrocytomas, and 12 anaplastic oligodendrogliomas) were measured using adapter-tagged competitive polymerase chain reaction, a high-throughput reverse transcription-polymerase chain reaction technique. We applied unsupervised and supervised principal component analyses to elucidate the prognostic molecular features of the gliomas. The gene expression data matrix was significantly correlated with the histological grades, oligo-astro histology, and prognosis. Using 110 gliomas, we constructed a prediction model based on the expression profile of 58 genes, resulting in a scheme that reliably classified the glioblastomas into two distinct prognostic subgroups. The model was then tested with another 42 tissues. Multivariate Cox analysis of the glioblastoma patients using other clinical prognostic factors, including age and the extent of surgical resection, indicated that the gene expression profile was a strong and independent prognostic parameter. The gene expression profiling identified clinically informative prognostic molecular features in astrocytic and oligodendroglial tumors that were more reliable than the traditional histological classification scheme. (Cancer Sci 2009; 100: 165-172).
引用
收藏
页码:165 / 172
页数:8
相关论文
共 42 条
[1]  
Afra D, 2002, LANCET, V359, P1011
[2]   Singular value decomposition for genome-wide expression data processing and modeling [J].
Alter, O ;
Brown, PO ;
Botstein, D .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (18) :10101-10106
[3]  
Aoki T, 2006, J NEUROSURG, V105, P385, DOI 10.3171/jns.2006.105.3.385
[4]   Randomized phase II study of temozolomide and radiotherapy compared with radiotherapy alone in newly diagnosed glioblastoma multiforme [J].
Athanassiou, H ;
Synodinou, M ;
Maragoudakis, E ;
Paraskevaidis, M ;
Verigos, C ;
Misailidou, D ;
Antonadou, D ;
Saris, G ;
Beroukas, K ;
Karageorgis, P .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (10) :2372-2377
[5]   Semi-supervised methods to predict patient survival from gene expression data [J].
Bair, E ;
Tibshirani, R .
PLOS BIOLOGY, 2004, 2 (04) :511-522
[6]   Bifunctional role for VEGF-induced heme oxygenase-1 in vivo: induction of angiogenesis and inhibition of leukocytic infiltration [J].
Bussolati, B ;
Ahmed, A ;
Pemberton, H ;
Landis, RC ;
Di Carlo, F ;
Haskard, DO ;
Mason, JC .
BLOOD, 2004, 103 (03) :761-766
[7]   Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas [J].
Cairncross, JG ;
Ueki, K ;
Zlatescu, MC ;
Lisle, DK ;
Finkelstein, DM ;
Hammond, RR ;
Silver, JS ;
Stark, PC ;
Macdonald, DR ;
Ino, Y ;
Ramsay, DA ;
Louis, DN .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1998, 90 (19) :1473-1479
[8]  
CHANG CH, 1983, CANCER-AM CANCER SOC, V52, P997, DOI 10.1002/1097-0142(19830915)52:6<997::AID-CNCR2820520612>3.0.CO
[9]  
2-2
[10]  
Committee of Brain Tumor Registry of Japan, 2003, NEUROL MED-CHIR, V43, P1, DOI [10.2176/nmc.43.S1, DOI 10.2176/NMC.43.S1]